Efficient and stable gene expression into human osteoclasts using an HIV-1-based lentiviral vector.
Kang Chu1, Kenneth G Cornetta, Michael J Econs
1Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA. kachu@iupui.edu
DNA and Cell Biology
|March 28, 2008
Summary
This study presents an efficient lentiviral vector method for gene transduction into human preosteoclasts. The method ensures stable gene expression without impacting osteoclast differentiation or function, offering a new tool for research.
Area of Science:
- Cell Biology
- Gene Therapy
- Molecular Biology
Background:
- Osteoclasts are terminally differentiated cells, making gene transduction challenging.
- Efficient and stable gene expression in osteoclasts is crucial for studying their biology and related disorders.
Purpose of the Study:
- To develop an efficient gene transduction method for human preosteoclasts using lentiviral vectors.
- To assess the impact of lentiviral transduction on preosteoclast differentiation and mature osteoclast function.
Main Methods:
- Human preosteoclasts were transduced with a replication-defective lentiviral vector carrying an enhanced green fluorescent protein (EGFP) reporter gene.
- Transduction efficiency was quantified using flow cytometry.
- Differentiated osteoclasts derived from transduced preosteoclasts were analyzed for viability, TRACP activity, and pit formation.
Main Results:
- Efficient gene transduction into human preosteoclasts was achieved at a multiplicity of infection of 10.
- Sustained EGFP expression was observed for over 4 weeks.
- Lentiviral transduction did not adversely affect osteoclast survival, differentiation, or functional capacity.
Conclusions:
- A robust lentiviral vector-based protocol enables efficient and stable gene transduction into human preosteoclasts.
- Transduced preosteoclasts can differentiate into functional mature osteoclasts, indicating the method's utility.
- This approach provides a valuable tool for investigating osteoclast biology and developing gene therapies for osteoclast-related diseases.
